110 results about "Gut barrier" patented technology

The invention discloses kluyveromyces marxianus KUST3801 for preventing and treating celiac disease, application of the kluyveromyces marxianus KUST3801 and a fruit and vegetable fermented beverage. The preservation number is CGMCC NO. 32767; the Kluyveromyces marxianus strain is classified and named as Kluyveromyces marxianus, and the Kluyveromyces marxianus strain is named as Kluyveromyces marxianus. The strain can be used for effectively preventing and treating celiac disease by protecting intestinal mucosa and intestinal barrier, regulating immunity and relieving inflammation. In addition, in the preparation of the fermented fruit and vegetable juice beverage, the aroma of the beverage can be improved, and the antioxidant activity is enhanced.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

The invention belongs to the field of food nutrition and functional factors, and particularly relates to a method for preparing ovotransferrin hydrolysate with high immunocompetence based on an adult gastrointestinal simulated digestion system. According to the method, ovotransferrin is treated through the stomach and intestine of a simulated adult, OVT hydrolysate is prepared, and the OVT hydrolysate contains HTEGSTT, TTSY and / or RTAGWVIPMG. The invention finds that the immunomodulatory activity of OVT is enhanced after gastrointestinal digestion and hydrolysis, the OVT is more easily hydrolyzed in simulated adult digestive juice than in infant digestive juice, and a contrast experiment shows that the nutrition intervention of OVT adult and infant simulated digestion products can promote the generation of short-chain fatty acids such as acetic acid, propionic acid and butyric acid; the swelling injury caused by inflammation to small intestine mucous membrane tissues is effectively relieved, so that the intestinal barrier immune function is obviously improved, and the OIA shows higher intestinal immune activity than the OIB.

According to the present invention, a method for producing a hot water extract of an aboveground portion of a plant of the genus aralia is characterized by comprising a step for adding sodium hydrogen carbonate.

The invention discloses a curcumin nanocrystal preparation as well as a preparation method and application thereof. The invention relates to a curcumin nanocrystal composition which is prepared by drying and curing a curcumin nanocrystal suspension to a blank pellet core, the curcumin nanocrystal suspension contains 20-35% of curcumin nanocrystals, 1-10% of a three-dimensional protective agent and 1-10% of a charge protective agent, and the average particle size of the curcumin nanocrystals is 200-320 nm. The curcumin nanocrystal composition prepared by the invention can effectively prevent and treat heat stroke and complications thereof, remarkably improve heat tolerance, prolong survival time, reduce the level of inflammatory factors in blood, protect intestinal epithelial cells and intestinal barrier functions, reduce damage caused by heat stroke, prevent and treat body and organ damage caused by heat stroke, and improve the curative effect of the curcumin nanocrystal composition. The preparation has the advantages of being high in drug loading capacity, good in stability, high in bioavailability, safe, effective, convenient to carry and the like.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

The invention relates to a nutritional composition for infants, for children as well as a medical nutritional composition, comprising human milk oligosaccharides and Bifidobacterium breve. The invention further relates to the use of said nutritional composition for strengthening the gut epithelial defense and / or the gut barrier function.

Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

The invention relates to a solid beverage for maintaining intestinal-brain axes as well as a preparation method and application of the solid beverage, and belongs to the technical field of food processing. The health-care tea powder consists of cold-extracted freeze-dried tea powder, theanine powder, fructus phyllanthi powder, PQQ powder or microencapsulated PQQ powder, targeted probiotic microcapsule powder, mogroside and galactooligosaccharide. During preparation, the cold-extracted freeze-dried tea powder, the microencapsulated PQQ powder and the purchased targeted probiotic microcapsule powder are respectively prepared and then are mixed with other raw materials. The innovation of the invention lies in that the intestine-brain axis is synergistically maintained through a four-dimensional mechanism of anti-inflammatory and anti-oxidation-neuromodulation-mitochondrial activation-flora intervention, and the activity of the components is guaranteed by adopting technologies of cold extraction freeze-drying, microencapsulation and the like. The system can inhibit enteropathogenic bacteria, repair intestinal barriers, protect nervous systems, improve cognitive functions and regulate intestinal flora, has high technical feasibility and market prospects, and makes remarkable progress compared with the prior art.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

This invention belongs to the field of anti-aging functional food technology, specifically relating to an anti-aging and longevity composition containing inactivated Akkermansia myxophilus. Existing anti-aging products are mostly single-ingredient products. The composition of this invention contains inactivated Akkermansia myxophilus, NMN, coenzyme Q10, resveratrol, and astaxanthin. This invention achieves the effects of delaying aging, improving muscle strength, and enhancing cognitive function by repairing the intestinal barrier, increasing NAD+ levels, and activating longevity pathways. The composition of this invention is stable at room temperature and can be formulated into capsules or powder.

The invention provides lactobacillus plantarum S7-12, fermented vegetables and application of the lactobacillus plantarum S7-12 and the fermented vegetables, and belongs to the technical field of microbial fermentation, the lactobacillus plantarum S7-12 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66578. The plant lactobacillus S7-12 has relatively strong growth ability, acid production ability, acid resistance and salt resistance, and fermented vegetables prepared from the plant lactobacillus S7-12 can be used for relieving weight loss and colon shortening caused by inflammatory bowel diseases, reducing disease activity indexes and visceral organ indexes, relieving intestinal mucosa structural damage, relieving oxidative stress injury of colon, and improving the immunity of the vegetables. The release of proinflammatory factors in serum and colon is reduced, the secretion of anti-inflammatory factors is improved, the expression quantity of colon tight junction protein is increased, the TLR4 pathway is activated, and the colon barrier function is improved; the method can be used for preparing health-care foods or medicines, and has a wide application prospect.

The application relates to the technical field of organ chip, and discloses a biocompatible membrane sheet, which comprises wave structures continuously distributed in one direction, and the wave structures are in a hollow structure. The biocompatible membrane sheet disclosed by the application has consistent hollow wrinkle forms, uniform deformation when the biocompatible membrane sheet is subjected to external force, better transmission and fluctuation, and can more truly reproduce the dynamic change state of an organ in vitro. The application further discloses an organ chip, an intestinal organ chip, an intestinal organ chip system, a membrane sheet preparation method, an intestinal organ chip preparation method and an intestinal barrier construction method.

This invention discloses Bifidobacterium microspheres for alleviating Salmonella typhimurium infection, their preparation method, and applications. It belongs to the field of microbial shell-core gel technology, and particularly relates to Bifidobacterium microspheres for alleviating Salmonella typhimurium infection. The Bifidobacterium microspheres are prepared by mixing a thermal copolymer with Bifidobacterium, then adding it dropwise to a calcium chloride aqueous solution for the first cross-linking, followed by immersion in a tannic acid aqueous solution for the second cross-linking. The thermal copolymer is obtained by mixing equal volumes of polysaccharide aqueous solution and protein aqueous solution. This invention provides Bifidobacterium microspheres for alleviating Salmonella typhimurium infection, their preparation method, and applications. The Bifidobacterium microspheres prepared by this invention achieve concentrated responsive release of Bifidobacterium in the cecum, improving intestinal retention and adhesion colonization efficiency. Their alleviating effect on Salmonella typhimurium infection exceeds that of free bacteria, exhibiting better intestinal barrier damage repair and flora regulation effects.

The invention belongs to the technical field of medicine and pharmacy, and particularly relates to application of an AP1B1 allosteric activator of ethyl gallate. In the invention, AP1B1 is a beta 1 subunit (AP1B1) of a linking factor associated protein complex 1 (AP-1), and is an essential component for assembling a functional AP-1B complex. The ethyl gallate is used as an allosteric activator of AP1B1 and is specifically combined with an allosteric pocket of the AP1B1 to induce the AP1B1 to generate conformational change, so that the vesicle transportation function of an AP1B complex is activated, and the substrate-side membrane protein sorting capacity is recovered. A target dependence experiment verifies that the effect of ethyl gallate on promoting tight junction protein ZO-1 expression and membrane localization in AP1B1 knocked-down Caco-2 cells is remarkably weakened, and it is prompted that the intestinal barrier protection function of ethyl gallate depends on AP1B1. The invention provides a new strategy for developing medicines for treating intestinal barrier injury related diseases.

The invention discloses an application of an lncRNA-MALAT1 / miR-145 / BNIP3 regulation axis in preparation of a medicine for treating hemorrhagic shock ischemia reperfusion intestinal injury. In existing treatment, conventional liquid resuscitation easily causes serious inflammation and pathological apoptosis, the intestinal barrier repair effect is limited, and the molecular mechanism is not completely clarified. The invention discloses that a regulatory axis participates in an intestinal injury process through a ceRNA mechanism (MALAT1 is used as miR-145 sponge to inhibit regulation of BNIP3 and mediate controlled programmed cell death instead of pathological apoptosis), and provides a new molecular target for treatment. The medicine aiming at the regulation shaft can relieve inflammatory response, reduce pathological apoptosis and promote intestinal barrier repair, and has a good application prospect.

The invention relates to application of golden chrysanthemum leaf extract in preparation of intestinal mucosal lesion products, and belongs to the technical field of medicine and health care products. The extract mainly comprises phenolic acid components, has no obvious visceral toxicity, and realizes protection of intestinal mucosal injury caused by hypoxia or chemical drugs by regulating intestinal barrier function, oxidative stress, inflammatory response and energy metabolism. The invention breaks through the limitation of the existing single-target drug, provides a multi-channel protection scheme, is suitable for developing anti-hypoxia functional products (such as drugs, health care products or foods), and improves the economic value of golden chrysanthemum leaf resources.

The invention belongs to the field of biological medicine, and particularly discloses an acute intestinal injury targeted therapy drug based on an MAIT cell viability evaluation algorithm and application thereof. The MAIT cell activity parameters (including CD3 + TCR beta + MR1 + cell proportion and IL-17A secretion volume) in a patient sample are detected through flow cytometry, quantification is carried out according to an algorithm activity score = (MR1 + cell proportion * 0.4) + (IL-17A concentration / 50 * 0.6), and the patient with the score larger than or equal to 2.0 is suitable for targeted therapy. An oral solution (with the concentration of 5-20 [mu] M) taking acetyl-6-formyl pterin (Ac-6FP) as a core is adopted for treatment, intestinal injury is relieved by specifically inhibiting the IL-17A secretion function of MAIT cells, the intestinal barrier function is remarkably improved in an animal model, and the survival rate is increased. Meanwhile, the matched kit integrates the antibody detection assembly and the Ac-6FP medicine, and diagnosis and treatment integration is achieved. The invention provides a precise targeted treatment strategy and medicine for acute intestinal injury.

This invention provides a composition for alleviating intestinal oxidative stress damage and its application, the composition comprising 4'-galactosyllactose (4'-GL) and glycomacropeptide (GMP). This invention found that, compared with the individual concentrations of 4'-GL and GMP, the composition of 4'-GL and GMP more significantly promotes the release of superoxide dismutase and catalase, while also more significantly reducing the release of malondialdehyde, a marker of oxidative stress. The synergistic effect between the two allows 4'-GL and GMP to better alleviate intestinal damage in Drosophila. Simultaneously, the composition can improve the survival rate and climbing index of H2O2-induced Drosophila, prolong the intestinal length of diseased Drosophila, improve the integrity of the intestinal barrier, and induce a recovery trend in the Drosophila. This demonstrates that the composition has a mitigating effect on intestinal oxidative stress damage.

The invention relates to an establishment method of a high-fat induced intestinal organ injury model and an injury intervention method for the model. The establishment method comprises the following steps: step A, preparation: preparing colon cells, PBMC cells and an organ-like culture chip for later use; step B, colon barrier construction: inoculating colon cells to the surface of a barrier membrane on the lower side of a culture chip by using an organoid culture chip to obtain a colon barrier model; step C, constructing a co-culture model, and inoculating PBMC cells to the basal side of the colon barrier on the basis of the colon barrier to obtain a human colon barrier-PBMC co-culture model; d, constructing a damage model, and performing damage treatment on the co-culture model by using a treating fluid to obtain the damage model; according to the invention, the barrier function organ-like chip is used, a human intestinal cell-PBMC co-culture model is formed by utilizing human intestinal organs and PBMC cells, and OXLDL / palmitic acid can play a role in an injured intestinal organ barrier model and form a high-fat induced intestinal organ injury model through the prepared injury treating fluid.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

The application provides a soluble acid polysaccharide of Phaseolus vulgaris, and also provides a preparation method and application of the soluble acid polysaccharide of Phaseolus vulgaris. The application also provides application of the soluble acid polysaccharide of Phaseolus vulgaris in preparation of a medicine for protecting the spleen and liver, having the ability of recovering the colon barrier, regulating intestinal flora, or a health-care food for enhancing the immunity of the body. The soluble acid polysaccharide of Phaseolus vulgaris can be extracted by hot water extraction or microwave-assisted low eutectic solvent extraction, especially, the polysaccharide extracted by the microwave-assisted low eutectic solvent extraction has better drug efficacy, is safer and more controllable, and provides a new selection for clinic.

Methods and systems for assessing gut barrier function with medical imaging techniques and orally ingested contrast are discussed herein. For example, a method for assessing gut health of a patient includes administering a contrast agent to the patient. The method further includes performing an magnetic resonance imaging (MRI) scan of the patient. The method further includes determining a metric corresponding to the contrast agent in a gut of the patient based on the performed MRI scan. The method further includes assessing health of the gut of the patient based on the metric corresponding to the contrast agent in the gut of the patient.

The present invention relates to the use of riboprine in the maintenance, improvement, or dietary management of gut barrier function. The riboprine may be formulated in an oral composition such as dietary supplement, a food product, a food for special medical purpose (FSMP) or a food for special dietary use (FSDU).

The present invention is directed to a dietary supplement composition for enhancing gut barrier and skin health comprising a therapeutically effective amount of: (a) at least one polysaccharide chosen from a fructo-oligosaccharide, a galacto-oligosaccharide, a xylo-oligosaccharide, and mixtures thereof; (b) at least one polysaccharide mucilage having demulcent activity; (c) at least one source of insoluble dietary fiber having antioxidant activity; (d) at least one amino acid capable of supporting gut barrier integrity; (e) at least one source of resistant starch; and, optionally (f) at least one natural ingredient capable of protecting gastric function.

This invention belongs to the field of food nutrition and functional factors, specifically relating to a method for preparing highly immunomodulatory ovotransferrin (OVT) hydrolysates based on an adult gastrointestinal simulated digestive system. The method involves processing OVT using a simulated adult gastrointestinal tract to prepare OVT hydrolysates containing HTEGSTT, TTSY, and / or RTAGWVIPMG. This invention reveals that OVT exhibits enhanced immunomodulatory activity after gastrointestinal digestion and hydrolysis, and is more readily hydrolyzed in simulated adult digestive fluids than in infant digestive fluids. Comparative experiments show that nutritional intervention with OVT simulated digestive products from adults and infants can promote the production of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid, effectively alleviate swelling and damage to the small intestinal mucosa caused by inflammation, significantly improve intestinal barrier immune function, and OVT IA exhibits higher intestinal immune activity than OVT IB.

The invention concerns the specific mixture of non-digestible saccharides that was found to be especially suitable for young children, facilitating the most favorable development of the microbiota from an infant-like to an adult-like type taking into account the composition as well as the metabolic activity, on top of that, enabling a high level of butyrate formation, resulting in improved gut barrier function.

The invention relates to a composition or a kit of parts comprising a probiotic and at least one human milk oligosaccharide (HMO), wherein the probiotic is the Bifidobacterium bifidum (B. bifidum) HA-132 strain (CNCM I-5898) or a strain having at least 97% average nucleotide identity with CNCM I-5898, and the at least one HMO is selected from a fucosylated HMO, a neutral core HMO, and a sialylated HMO, or is any mixture thereof, for use in supporting or improving cognitive development, emotional and behavioural development, immune system development and anti-inflammatory support, gut barrier function, and / or gut motility, in a subject. The invention further relates to a nutritional composition comprising a probiotic and at least one HMO, wherein the probiotic is the B. bifidum HA-132 strain (CNCM I-5898) or a strain having at least 97% average nucleotide identity with CNCM I-5898, and the at least one HMO is a sialyllactose.

Bacillus strain compositions and methods for converting (i) one or more polysaccharides into short chain polysaccharides and / or monosaccharides and / or (ii) one or more proteins into short chain polypeptides and / or amino acids are provided. The Bacillus strain composition can comprise Bacillus subtilis 750 or an active variant thereof, and optionally at least one of Bacillus subtilis 747, Bacillus subtilis 839, Bacillus subtilis 1781, Bacillus subtilis 1999, Bacillus subtilis 2018, or an active variant thereof. Compositions provided herein can be fed to animals in an effective amount to increase digestibility of one or more polysaccharides and / or one or more proteins; increase nutrition efficiency and / or energy partitioning; increase nutrient absorption; enhance gut immunity and / or gut barrier integrity; and / or inhibit a pathogen in the gastrointestinal tract of the animal.